Nls pharmaceutics ceo issues letter to shareholders

Zurich, switzerland / accesswire / december 29, 2023 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announces that its chief executive officer, alex zwyer, has issued the following letter to shareholders: nls pharmaceutics ceo issues letter to shareholders to our shareholders and friends, in 2023, there were significant challenges both within the healthcare sector and around the globe, from the ongoing wars in ukraine and the middle east, adjusting to a post-pandemic world, to growing geopolitical tensions and widespread political division.
NLSP Ratings Summary
NLSP Quant Ranking